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Tolerogenic Vaccination Exploiting 
Apoptotic Mechanisms via Erythrocyte-to-
Hepatic/Splenic Targeting 
Jeffrey A. Hubbell
Institute of Bioengineering, EPFL
Thinking about surveillance: seeking 
pathogens
Lymph Nodes (invader/self) Mucosae (invader/friendly)
Thinking more carefully about 
surveillance: seeking pathogens, seeking self
Lymph Nodes (invader/self) Mucosae (invader/friendly)
Spleen (self/invader)
Liver (mostly self)
Antigen-presenting cells in immunity
Immature DCs Mature DCs
Deletion          Regulation Various flavors of immunity…
Tolerogenic Vaccines
 Question: How do we target the liver and 
spleen, for self-antigen presentation –
induction of immunological tolerance
 Multiple driving needs:
 Protein drugs, non-human origin, or in protein 
replacement therapies, e.g. factor VIII in 
hemophilia A
 Prophylactic and therapeutic
 Re-establishment of immunological tolerance in 
autoimmunity
 Therapeutic, but maybe prophylactic
Harnessing Peripheral Tolerance
Central Tolerance:
Deletion in the thymus – born with it,
and cannot modify it
Education by 
Peripheral Deletion:
Simple molecular approach 
to accomplish the same 





Apoptotic Cell Debris Induces Tolerogenic 
Antigen Presentation 
Cells die all the time. How do we not develop immunity to 
dying cells?  Why don’t we all develop autoimmunity?
Debris from dying cells induce peripheral tolerance:
Antigen-presenting 
cells doing 
surveillance Deleting or exhausting
the antigen-specific T 
cells
Very direct, antigen-specific modulation of the immune system

















But antigen chemically 
conjugated to apoptotic 
autologous cells would be a 
very complex product…
Exploiting Erythrocyte Apoptosis (eryptosis)
The Challenge:  How do we mimic dying cell debris?
Red blood cells die at 1% per day in an apoptosis-like 
process (eryptosis)
Binding Exogenous Antigens to Erythrocytes in 
situ: seek simple, vaccine-like injections
scFv fusionBinding 
glycophorin A 









Discovering Affinity Ligands for 
Erythrocytes – target is glycophorin A
Library
round 4 Library ERY1
anti-phage-PE
Flow cytometric analysis of erythrocyte 
binding of phage from round 4 of the 
selection
The best clone from round 4, clone 
ERY1, displaying the sequence 
WMVLPWLPGTLD 
Fluorescence from bound 
phagecell
phage
Kontos, Hubbell.  Molecular Pharmaceutics. 2010
Fluorescence from bound 
phage
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ERY1-OVA Binds both Healthy and 
Eryptotic Erythrocytes In Vivo
Young cells
Eryptotic cells
So, all populations of 
red blood cells are 
targeted
ERY1-OVA Binding Induces no Changes 
in Erythrocyte Circulation Characteristics

















































































Erythrocyte binding Modulates Uptake by 
APCs in the Spleen and Liver
















A Decisive Model:  OTI Mice, transgenic 
for the T cell receptor for OVA
















































































Proliferation dilutes CFSE signal
spleen
saline antigen
A Decisive Model:  OTI Mice, transgenic 
for the T cell receptor for OVA










day 1, 6: tolerize i.v.
day 15: challenge with 
antigen + adjuvant
day 19: characterize inflammatory
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Antigen presentation is as efficient as 




































































spleen: PD-1+ OTI generations






































Erythrocyte binding induces profound 























































Erythrocyte binding induces profound 



























Erythrocyte-binding antigen enables cell 
survival vs. CD8 T cell mediated death





















































































Erythrocyte-binding antigen enables cell 























































Adoptive transfer of 
5 106 BDC2.5 CD4 T cells, 
reactive to the islet 
beta cell antigen 
chromogranin (p31).
p31 = free antigen
TER119-p31 = scFv fusion
Erythrocyte-binding antigen enables cell 











Erythrocyte-binding antigen enables cell 







































Many protein drugs induce immune 
reactions
Used to treat 100% of cases with ALL, with methotrexate
Immunity develops in 100% of patients and limits efficacy
Very difficult, demonstrative example, 
due to the bacterial origin of the drug
Erythrocyte-binding protein drugs escape 
immunity
Comparing WT asparaginase to RBC-binding version
Antibody response measured 21 days after the last injection
6 Dose









































Erythrocyte-binding protein drugs protects 




Comparing WT asparaginase to RBC-binding version
After tolerance induction, challenge with WT
Antibody response measured 21 days after the last injection
6000-fold reduction in immune response











































Potential and paths – tolerogenic 
vaccination
 De-immunization of protein therapeutics, e.g. 
factor VIII in hemophilia (and many others; in 
hemophilia, ~25% immune responders), 
bacterial enzymes, second-generation 
proteins
 Re-education of autoimmunity with known 
antigens and a cellular mechanism of 























In the lab that day: Sachiko Hirosue, Conlin
O’Neil, Diana Velluto, Alexandre de Titta
